WO2015049645A3 - An improved process for the preparation of dasatinib - Google Patents

An improved process for the preparation of dasatinib Download PDF

Info

Publication number
WO2015049645A3
WO2015049645A3 PCT/IB2014/064988 IB2014064988W WO2015049645A3 WO 2015049645 A3 WO2015049645 A3 WO 2015049645A3 IB 2014064988 W IB2014064988 W IB 2014064988W WO 2015049645 A3 WO2015049645 A3 WO 2015049645A3
Authority
WO
WIPO (PCT)
Prior art keywords
dasatinib
preparation
improved process
formula
relates
Prior art date
Application number
PCT/IB2014/064988
Other languages
French (fr)
Other versions
WO2015049645A2 (en
Inventor
Venkatraman JAYARAMAN
Samir Patel
Samir Mistry
Bhupendra Parmar
Original Assignee
Alembic Pharmaceuticals Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alembic Pharmaceuticals Limited filed Critical Alembic Pharmaceuticals Limited
Priority claimed from IN3169MU2013 external-priority patent/IN2013MU03169A/en
Publication of WO2015049645A2 publication Critical patent/WO2015049645A2/en
Publication of WO2015049645A3 publication Critical patent/WO2015049645A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

The present invention relates to a novel synthetic route to N-(2-chloro-6-methylphenyl)- 2-[[6-[4-(2-hydroxyethyl)-l-piperazinyl] -2-methyl-4-pyrimidyl] amino]-5- thiazolformamide of the formula I and also relates to the process for the preparation of novel amorphous forms of dasatinib (formula I).
PCT/IB2014/064988 2013-10-04 2014-10-01 An improved process for the preparation of dasatinib WO2015049645A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IN3169/MUM/2013 2013-10-04
IN3633MU2013 2013-11-19
IN3633/MUM/2013 2013-11-19
IN3169MU2013 IN2013MU03169A (en) 2013-10-04 2014-10-01

Publications (2)

Publication Number Publication Date
WO2015049645A2 WO2015049645A2 (en) 2015-04-09
WO2015049645A3 true WO2015049645A3 (en) 2015-08-13

Family

ID=52779241

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2014/064988 WO2015049645A2 (en) 2013-10-04 2014-10-01 An improved process for the preparation of dasatinib

Country Status (1)

Country Link
WO (1) WO2015049645A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017108605A1 (en) 2015-12-22 2017-06-29 Synthon B.V. Pharmaceutical composition comprising amorphous dasatinib
WO2017134617A1 (en) * 2016-02-03 2017-08-10 Dr. Reddy's Laboratories Limited Process for the preparation of amorphous dasatinib
CN106008392B (en) * 2016-06-09 2018-05-04 山东恒辰生物科技有限公司 A kind of preparation method of the intermediate of cancer therapy drug Dasatinib
WO2018078392A1 (en) 2016-10-29 2018-05-03 Cipla Limited Polymorphs of dasatinib
JP2020526528A (en) * 2017-07-07 2020-08-31 バイオコン・リミテッド Polymorphic form of dasatinib
CN115569137A (en) 2018-06-15 2023-01-06 汉达癌症医药责任有限公司 Salts of kinase inhibitors and compositions thereof
CN111217807A (en) * 2018-11-26 2020-06-02 安礼特（上海）医药科技有限公司 Dasatinib amorphous form and preparation method thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060004067A1 (en) * 2004-02-06 2006-01-05 Bang-Chi Chen Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors
WO2009053854A2 (en) * 2007-10-23 2009-04-30 Teva Pharmaceutical Industries Ltd. Polymorphs of dasatinib and process for preparation thereof
WO2010139980A1 (en) * 2009-06-03 2010-12-09 Generics [Uk] Limited Process for preparing crystalline dasatinib monohydrate
WO2013065063A1 (en) * 2011-11-03 2013-05-10 Cadila Healthcare Limited Anhydrous form of dasatinib, process for its preparation and its use

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060004067A1 (en) * 2004-02-06 2006-01-05 Bang-Chi Chen Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors
WO2009053854A2 (en) * 2007-10-23 2009-04-30 Teva Pharmaceutical Industries Ltd. Polymorphs of dasatinib and process for preparation thereof
WO2010139980A1 (en) * 2009-06-03 2010-12-09 Generics [Uk] Limited Process for preparing crystalline dasatinib monohydrate
WO2013065063A1 (en) * 2011-11-03 2013-05-10 Cadila Healthcare Limited Anhydrous form of dasatinib, process for its preparation and its use

Also Published As

Publication number Publication date
WO2015049645A2 (en) 2015-04-09

Similar Documents

Publication Publication Date Title
WO2015049645A3 (en) An improved process for the preparation of dasatinib
EA201201082A1 (en) PHARMACEUTICAL COMPOSITION CONTAINING N- (2-CHLOR-6-METHYLPHENYL) -2 - [[6- [4- (2-HYDROXYETHYL) -1-PIPERASINYL] -2-METHYL-4-PYRIMIDINYL] AMON) ch) ch)
PH12014501719B1 (en) Pyridone derivatives
IL242278A0 (en) Substituted n-(4-fluoro-2-methoxy-5-nitrophenyl)pyrimidin-2-amine compounds, and salts thereof
CA2826751C (en) Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds
SG11201806683UA (en) Tlr7 agonist crystalline form a, preparation method and use thereof
WO2015008218A3 (en) Process for the preparation of suvorexant and intermediates useful in the synthesis of suvorexant
WO2014132270A3 (en) Process for the preparation of 2-(2-aminothiazol-4-yl)-n-[4-(2-{[(2r)-2-hydroxy-2-phenyl ethyl]amino}ethyl)phenyl]acetamide monohydrochloride, its intermediates and polymorph thereof
WO2013150545A3 (en) Process for preparation of benzimidazole derivatives and salts thereof
WO2018029711A3 (en) Process for the preparation of venetoclax
WO2012107890A3 (en) Crystal forms of lurasidone chlorhydrate
MX2015017156A (en) Bace inhibitors.
WO2015068175A3 (en) An improved process for the preparation of pazopanib or a pharmaceutically acceptable salt thereof
PH12015500795B1 (en) N-(2-(cyclic amine)ethyl)benzamide derivatives as p2x7 inhibitors
NZ720340A (en) Synthesis of trans-8-chloro-5-methyl-1 -[4-(pyridin-2-yloxy)-cyclohexyl]-5,6-dihydro-4h-2,3,5,10b-tetraaza-benzo[e]azulene and crystalline forms thereof
PH12015501146A1 (en) Hydantoin derivative
WO2013157019A3 (en) Process for preparing dasatinib monohydrate
MX351610B (en) ACID ADDITION SALTS OF 5a-HYDROXY-6ß-[2-(1H-IMIDAZOL-4-YL)ETHYL AMINO]CHOLESTAN-3ß-OL.
EA201600123A1 (en) DERIVATIVES 1- (PIPERAZIN-1-IL) -2 - ([1,2,4] TRIAZOL-1-IL) ETHANON
IN2013CH04511A (en)
EP3006449A4 (en) METHOD FOR SYNTHESIZING OPTICALLY ACTIVE -AMINO ACID USING CHIRAL METAL COMPLEX COMPRISING AXIALLY CHIRAL N-(2-ACYLARYL)-2-[5,7-DIHYDRO-6H-DIBENZO[c,e]AZEPIN-6-YL]ACETAMIDE COMPOUND AND AMINO ACID
WO2013179298A3 (en) A process for preparation of phenyl carbamate derivative and polymorphic forms thereof
IN2013MU04056A (en)
IN2013MU03169A (en)
WO2014030173A3 (en) Improved process for preparation of atazanavir bisulfate

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14850515

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 14850515

Country of ref document: EP

Kind code of ref document: A2